GRI Bio, Inc

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell GRI Bio, Inc and other ETFs, options, and stocks.

About GRI

GRI Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapies for inflammatory, fibrotic, and autoimmune diseases. It focuses on its lead program, GRI-0621, an inhibitor of type 1 invariant Natural Killer T (iNKT) cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis. 

CEO
W. Marc Hertz
CEOW. Marc Hertz
Employees
4
Employees4
Headquarters
La Jolla, California
HeadquartersLa Jolla, California
Founded
2009
Founded2009
Employees
4
Employees4

GRI Key Statistics

Market cap
2.34M
Market cap2.34M
Price-Earnings ratio
-0.03
Price-Earnings ratio-0.03
Dividend yield
Dividend yield
Average volume
2.54M
Average volume2.54M
High today
$0.4786
High today$0.4786
Low today
$0.395
Low today$0.395
Open price
$0.4695
Open price$0.4695
Volume
1.20M
Volume1.20M
52 Week high
$15.64
52 Week high$15.64
52 Week low
$0.395
52 Week low$0.395

Stock Snapshot

GRI Bio, Inc(GRI) stock is priced at $0.42, giving the company a market capitalization of 2.34M. It carries a P/E multiple of -0.03.

During the trading session on 2025-12-18, GRI Bio, Inc(GRI) shares reached a daily high of $0.48 and a low of $0.40. At a current price of $0.42, the stock is +6.2% higher than the low and still -12.3% under the high.

Trading activity shows a volume of 1.2M, compared to an average daily volume of 2.54M.

The stock's 52-week range extends from a low of $0.40 to a high of $15.64.

The stock's 52-week range extends from a low of $0.40 to a high of $15.64.

GRI News

TipRanks 2d
Promising Potential of GRI-0621 in IPF Treatment: A Buy Recommendation by Matthew Keller

Analyst Matthew Keller of H.C. Wainwright reiterated a Buy rating on GRI Bio, retaining the price target of $10.00. Claim 50% Off TipRanks Premium and Invest wi...

TipRanks 5d
GRI Bio Closes $8 Million Public Offering

Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper...

Benzinga 7d
GRI Bio Drug Shows Promising Lung Function Recovery In Patients With Thickened Lungs

GRI Bio, Inc. (NASDAQ:GRI) on Wednesday shared topline data from the Phase 2a GRI-0621-IPF-02 trial evaluating GRI-0621 for idiopathic pulmonary fibrosis. IPF...

People also own

Based on the portfolios of people who own GRI. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.